JPRN-UMIN000018866已完成未知
Phase IIb study of SNJ-1656; A dose-response study in patients with primary open angle glaucoma or ocular hypertension - A dose-response study of SNJ-1656 in patients with primary open angle glaucoma or ocular hypertension
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Active retinal disease 2)History of keratorefractive surgery or filtering surgery 3)History of trabeculotomy or laser trabeculoplasty in the study eye 4)Highly visual field loss 5)Corneal abnormalities that would preclude accurate readings with an applanation tonometer 6)Ocular surgery within 90 days 7)Use of contact lenses 8)Any active ocular disease other than glaucoma or OH 9)Uncontrolled systemic disease (eg, hepatic, renal, cardiovascular or endocrine system disease) 10)Women who were pregnant, nursing or who were of childbearing potential, or planning a pregnancy
研究者
相似试验
已完成
不适用
Phase IIa study of SNJ-1656; An exploration study in patients with primary open angle glaucoma or ocular hypertensioPrimary open-angle glaucoma (POAG) or Ocular hypertension (OH)JPRN-UMIN000009648Senju Pharmaceutical co.,ltd.60
进行中（未招募）
不适用
This is a clinical study designed to explore the safety, effectiveness and optimum dose of the medicine MED-563 in adult patients who suffer from asthma that is not fully controlled by other treatmentsncontrolled AsthmaMedDRA version: 14.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-020126-17-BGAstraZeneca AB482
已完成
2 期
A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque PsoriasisPlaque PsoriasisNCT05223868Janssen Research & Development, LLC255
已完成
不适用
A phase II dose-response study to assess the safety and efficacy of SJP-0035 in patients with corneal epithelial disorderCorneal epithelial disorderJPRN-UMIN000034199Senju Pharmaceutical Co.,Ltd.90
已完成
2 期
A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With NarcolepsyNarcolepsyNCT00424931Alza Corporation, DE, USA16